Amarin Corp. 6K - 010306
FORM
6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the
month of January, 2006
Commission
File Number 0-21392
(Translation
of registrant's name into English)
7
Curzon
Street, London W1J 5HG, England
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:
Form
20-F x
Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Yes
o
No
x
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form
6-K
if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Yes
o No
x
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant
is
incorporated, domiciled or legally organized (the registrant's "home country"),
or under the rules of the home country exchange on which the registrant's
securities are traded, as long as the report or other document is not a press
release, is not required to be and has not been distributed to the registrant's
security holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on
EDGAR.
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o
No
x
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
This
report on Form 6-K is hereby incorporated by reference in (a) the
registration statement on Form F-3 (Registration No. 333-104748) of Amarin
Corporation plc and in the prospectus contained therein, (b) the
registration statement on Form F-3 (Registration No. 333-13200) of Amarin
Corporation plc and in the prospectus contained therein, (c) the
registration statement on Form F-3 (Registration No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein, (d) the registration
statement on Form F-3 (Registration No. 333-121431) of Amarin Corporation plc
and in the prospectus contained therein and (e) the registration statement
on
Form F-3 (Registration No. 333-121760) of Amarin Corporation plc and in the
prospectus contained therein, and this report on Form 6-K shall be deemed a
part
of each such registration statement from the date on which this report is filed,
to the extent not superseded by documents or reports subsequently filed or
furnished by Amarin Corporation plc under the Securities Act of 1933 or the
Securities Exchange Act of 1934.
EXHIBIT
LIST
Exhibit
|
Description
|
|
|
99.1
|
Press
release dated January 3, 2006 titled:
Amarin
Licenses Phase IIb/III Drug for the Treatment of Fatigue in Multiple
Sclerosis to Multicell Inc.
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
AMARIN
CORPORATION PLC
By:
/s/
Richard A. B. Stewart
Richard A. B. Stewart
Chief Executive Officer
|
Date:
January 3, 2006